06 May 2025
06 May 2025
The funds will reportedly be allocated for R&D, technology advancements, and enhancing domestic manufacturing capacity.
The Swiss Biotech Report 2025 has indicated that R&D investment in Switzerland increased in 2024, compared to 2023.
Pliant is slashing 45% of its workforce in a move to 鈥渕inimise costs and preserve cash reserves鈥�.
More and more companies are investing in developing GLP-1R agonists, including dual and triple agonists and combination therapies.
As of 30 April, Selarsdi is available and interchangeable in all presentations that correspond with Stelara.
Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.
The agency鈥檚 decision on the NDA is expected in the fourth quarter of this year.
Approval in the UK was supported by the outcomes from two Phase III trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
